Instrument NamePfizer IncInstrument Symbol(PFE-N)

Instrument ExchangeNYSE

Pharmaceutical giant Pfizer (PFE) has named company veteran Chris Boshoff its chief of research and ...

Every company faces challenges. Sometimes, those issues are deeply damaging to a corporation's investment thesis. Other times, though, that's not the case, and the price drop represents a great buying opportunity for long-term investors. There are...

Collecting an above-average dividend payment can sometimes come with risks. High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to support its dividend payments. But that doesn't mean...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) .

/CNW/ -- TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative...

Most U.S. stocks ticked higher to recover some of their sharp slide from last week

High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible Trump-era tariffs could complicate the Fed's plans, several blue-chip dividend powerhouses like AT&T and Altria have...

December S&P 500 E-Mini futures (ESZ24) are down -0.14%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.12% this morning as market participants looked ahead to an earnings report from semiconductor stalwart Nvidia, a new batch of U.S. economic data, and comments from Federal Reserve officials.

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

U.S. stocks fell to their worst loss since Election Day as the boost that Wall Street got from last week’s victory for Donald Trump and a cut to interest rates by the Federal Reserve kept fading

Global Markets Canadian Markets The Toronto Stock Exchange (TSX), dropped significantly as both oil and gold prices declined. The slide in commodities was largely driven by concerns over waning demand from China, the world’s largest consumer of commodities, and a market shift due to expectations that U.S. interest rate cuts...

Thursday's trading session revealed 33 call options with unusually high activity and boasting expiration dates of 365 days or more. Three have emerged as promising long-term investments from this diverse pool of potential opportunities.

Volatility has tanked since the election, with the VIX Index closing at 14.02 yesterday. When volatility is low, options become cheaper, so today we’re taking a look at the Long Straddle Screener.

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +0.02%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.16%. Stocks on Wednesday settled mixed. The overall market found support from the as-expected US...

Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.

High yields aren't a warning indicator with these three stocks.

More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

The Dow Jones Industrial Average's shift away from value and income could open the door for other mega-cap growth stocks.

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy right now.

Pfizer is trading above its 52-week low but is still a dirt cheap buy.

These stocks near 52-week lows could be ready to rebound.

An activist investor has correctly identified a dysfunctional area of the business.

This pharmaceutical giant's Q3 numbers came in ahead of Street estimates.

However, don’t expect big immediate gains

Wall Street's bearish take on this proven innovator may not be warranted.